FGEN - FibroGen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
59.00
+2.70 (+4.80%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close56.30
Open56.95
Bid57.00 x 2900
Ask63.00 x 800
Day's Range56.80 - 59.30
52 Week Range40.74 - 68.55
Volume401,821
Avg. Volume441,984
Market Cap4.976B
Beta2.94
PE Ratio (TTM)N/A
EPS (TTM)-1.58
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est71.40
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about FibroGen Inc.
    Markityesterday

    See what the IHS Markit Score report has to say about FibroGen Inc.

    Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding FGEN is favorable, with net inflows of $4.46 billion.

  • Reuters2 days ago

    Focus: AstraZeneca plots China robot offensive to counter price cuts

    WUXI, China/LONDON (Reuters) - With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China. Tech tie-ups with the likes of Alibaba and Tencent will not directly lift the British group's drug sales, since they are not specific for any one company's products and in many cases will be low-cost or free. "Down the line we benefit, our products benefit, because we have better relationships with doctors and hospital managers and also because we diagnose more patients and they get better treated," Chief Executive Pascal Soriot told Reuters.

  • See what the IHS Markit Score report has to say about FibroGen Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about FibroGen Inc.

    Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $751 million over the last one-month into ETFs that hold FGEN are among the lowest of the last year and appear to be slowing.

  • Markit6 days ago

    See what the IHS Markit Score report has to say about FibroGen Inc.

    Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $1.12 billion over the last one-month into ETFs that hold FGEN are among the lowest of the last year and appear to be slowing.

  • GlobeNewswire9 days ago

    FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis

    FibroGen, Inc. (FGEN), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This follows review of the Phase 2 clinical data evaluating pamrevlumab in a placebo-controlled trial and represents recognition by the FDA that pamrevlumab has the potential to address an unmet medical need for this disease. “This Fast Track designation reflects recognition of the great need for a new therapeutic to help patients diagnosed with IPF to reduce the burden and progression of this debilitating disease and another positive step in developing pamrevlumab for the treatment of IPF,” said Elias Kouchakji, M.D., Senior Vice President, Clinical Development and Drug Safety.

  • Reuters16 days ago

    Boost for "made in China" medicine as Chi-Med wins key approval

    Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine. The London-listed company - which is known as Chi-Med and is collaborating with Eli Lilly on the drug - said on Wednesday that the National Medical Products Administration of China had approved Elunate or fruquintinib in colorectal cancer.

  • See what the IHS Markit Score report has to say about FibroGen Inc.
    Markit29 days ago

    See what the IHS Markit Score report has to say about FibroGen Inc.

    Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold FGEN had net inflows of $2.95 billion over the last one-month.

  • GlobeNewswirelast month

    New Research: Key Drivers of Growth for comScore, Fonar, FibroGen, Resolute Energy, National Commerce, and THL Credit — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of comScore, ...

  • See what the IHS Markit Score report has to say about FibroGen Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about FibroGen Inc.

    Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold FGEN had net inflows of $741 million over the last one-month.

  • FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
    Zackslast month

    FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates

    FibroGen (FGEN) delivered earnings and revenue surprises of 51.72% and 53.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    FibroGen: 2Q Earnings Snapshot

    The San Francisco-based company said it had a loss of 28 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...

  • GlobeNewswirelast month

    FibroGen Reports Second Quarter 2018 Financial Results

    Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018. Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic Cancer. Conference Call ...

  • GlobeNewswire2 months ago

    FibroGen to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018

    SAN FRANCISCO, Aug. 01, 2018-- FibroGen, Inc., a biopharmaceutical company, today announced that it will report second quarter 2018 financial results on Tuesday, August 7, 2018, after market close, and ...

  • ACCESSWIRE2 months ago

    Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on FGEN sign up now at www.wallstequities.com/registration. Pre-market, WallStEquities.com evaluates EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG), EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT), Fate Therapeutics Inc. (NASDAQ: FATE), and FibroGen Inc. (NASDAQ: FGEN).

  • ACCESSWIRE3 months ago

    Blog Exposure - FibroGen Completed Enrollment in US Phase-3 Clinical Program for Roxadustat in CKD Associated Anemia

    LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want access to our free research report on FibroGen, Inc. (NASDAQ: FGEN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=FGEN as the Company's latest news hit the wire. On June 07, 2018, the Company announced that it has completed patient enrollment in the Phase-3 studies supporting the US new drug application (NDA) submission for Roxadustat in anemia associated with chronic kidney disease (CKD).

  • See what the IHS Markit Score report has to say about FibroGen Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about FibroGen Inc.

    Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • FibroGen Inc (NASDAQ:FGEN) Investors Are Paying Above The Intrinsic Value
    Simply Wall St.4 months ago

    FibroGen Inc (NASDAQ:FGEN) Investors Are Paying Above The Intrinsic Value

    I am going to run you through how I calculated the intrinsic value of FibroGen Inc (NASDAQ:FGEN) using the discounted cash flow (DCF) method. Anyone interested in learning a bitRead More...

  • Benzinga4 months ago

    FibroGen Upgraded By Mizuho On Continued R&D Progress

    A combination of slightly better-than-expected first-quarter earnings and potential regulatory approval on the horizon have solidified one analysts faith in FibroGen Inc (NASDAQ: FGEN ) moving towards ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of FGEN earnings conference call or presentation 9-May-18 9:00pm GMT

    Q1 2018 FibroGen Inc Earnings Call

  • Associated Press4 months ago

    FibroGen: 1Q Earnings Snapshot

    The San Francisco-based company said it had a loss of 50 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...